Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10017895 | 1.00 | CA1 (0.59) | CA1CA2CTSKBTKHSD11B1 | |
| SCHEMBL12026537 | 1.00 | CA1 (0.59) | CA1CA2CTSKBTKHSD11B1 | |
| SCHEMBL14024975 | 0.91 | CTSK (0.59) | CA1CA2CTSKBTKHSD11B1 | |
| SCHEMBL21779949 | 0.91 | CTSK (0.59) | CA1CA2CTSKBTKHSD11B1 | |
| SCHEMBL12026411 | 0.91 | CTSK (0.59) | CA1CA2CTSKBTKHSD11B1 | |
| SCHEMBL26109825 | 0.91 | CA1 (0.55) | CA1CA2CTSKBTKHSD11B1 | |
| SCHEMBL17789650 | 0.89 | CA1 (0.52) | CA1CA2CTSKBTKHSD11B1 | |
| SCHEMBL26093192 | 0.87 | CA1 (0.57) | CA1CA2CTSKBTKHSD11B1 | |
| SCHEMBL19019381 | 0.85 | CTSK (0.57) | CA1CA2CTSKBTKHSD11B1 | |
| SCHEMBL27426504 | 0.85 | HRH3 (0.43) | CA1CA2CTSKHSD11B1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578060-B2 | JAK3 selective inhibitor | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2023-02-14 | — | — | US | disclosed |
| EP-2710018-B1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2021-12-29 | — | — | EP | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | EISAI CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | MYT1, AQP4, AQP1 | CA1 371/4885CA2 827/4885CTSK 1630/4885 |
| US-11578060-B2 | JAK3 selective inhibitor | JAK3, JAK1, JAK2 | CA1 4455/4885CA2 3962/4885CTSK 2021/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | CA1 70/4885CA2 76/4885CTSK 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.